About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Therapy Improves Outcomes for Patients With B-cell Lymphoma

by Colleen Fleiss on December 3, 2018 at 9:32 AM
Font : A-A+

Therapy Improves Outcomes for Patients With B-cell Lymphoma

Fifty-two percent of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) responded favorably to the therapy -- Forty percent had a complete response and 12 percent had a partial response, revealed phase-2 study of tisagenlecleucel (marketed as KYMRIAH®), to be published in the New England Journal of Medicine. In their phase-2 study of tisagenlecleucel (marketed as KYMRIAH®), to be published on-line Dec. 1, 2018 in the New England Journal of Medicine, an international team of researchers evaluated 93 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). They found that 52 percent of those patients responded favorably to the therapy. Forty percent had a complete response and 12 percent had a partial response.

Sixty-five percent of those patients--recruited from 27 sites in North America, Europe, Australia and Asia--were relapse free one year later, including 79 percent of the complete responders. The median progression-free survival for patients in this trial, known as JULIET; NCT02445248, "has not been reached," the authors note.

Advertisement

This compares favorably with earlier studies based on chemotherapy. The retrospective SCHOLAR-1 study, published in 2017, found that only seven percent of patients with refractory DLBCL had a complete response. The median overall survival was a mere 6.2 months. "Outcomes were consistently poor across patient subgroups and study cohorts," the SCHOLAR-1 authors noted.

More promising data from the JULIET trial "led to the Food and Drug Administration's approval May 1, 2018 of tisagenlecleucel for treatment of DLBCL," said study co-author Michael Bishop, MD, Professor of Medicine and Director of the Cellular Therapy Program at the University of Chicago Medicine. "Our current results are a promising sign of the potential for long-term benefit."
Advertisement

Scott McIntyre, the first patient to receive CAR-T cell therapy for stage 3 DLBCL at the University of Chicago, was pleased to learn about the study results. He is now 30 months post treatment and has had no sign of recurrence. He still gets a transfusion of antibodies every two months to protect him from the risk of infection that comes with the loss of his normal B cells. But the South Bend, Indiana native quickly returned to his job and seldom misses a Notre Dame football game. He just returned from watching the undefeated team beat the University of Southern California.

The JULIET trial, based at the University of Pennsylvania, is a single-arm, open-label, global study in adults with relapsed or refractory DLBCL. Patients who were enrolled had received at least two previous lines of therapy.

The treatment process is complicated. The care team takes blood from the patient, extracts T-cells and returns everything else. The T cells were shipped to Novartis' Morris Plains facility in New Jersey. The team there modified the T lymphocytes, enabling them to find disease-causing B cells that display a surface protein called CD19 and destroy them.

Once the T cells are returned to the hospital and re-infused into the patient, they multiply rapidly, producing millions of offspring. They quickly launch a vigorous assault on cells that display CD19, leading to the rapid destruction of cancerous cells.

The process, a form of immunotherapy, can have severe but generally self-limited side effects. The most common adverse event is cytokine release syndrome (58 percent), which causes severe flu-like symptoms such as fevers, swelling and low blood pressure. It can also cause neurologic effects such as delirium, but physicians have learned how to control these side effects. No deaths in this trial were attributed to the treatment.

McIntyre experienced mild cytokine release syndrome and some neurologic effects, but responded quickly to drugs designed to limit these side effects.

"The median progression-free survival has not been reached for complete responders," the authors wrote. The probability of survival at month 12 "was 90 percent among complete responders." "Overall, this is extremely exciting," Bishop said. "Relapses after 12 months are infrequent. Our first patient, treated in May 2016, has been back at work for two and a half years. This trial demonstrates that CAR-T cell therapy can provide a high rate of durable responses."

JULIET is the largest study examining a CAR-T therapy in DLBCL. It has enrolled patients from 27 sites in 10 countries across the US, Canada, Australia, Japan and Europe, including: Austria, France, Germany, Italy, Norway and the Netherlands.

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Cancer News

Telephone-based Weight Loss Program Helps Breast Cancer Patients Shed Pounds
Breast cancer patients in the obese or overweight category can greatly benefit from a telephone-based weight management program in achieving significant weight loss.
 Tobacco Use Among Cancer Patients Likely to Increase Symptom Burden
A new study assessed the association of cigarette smoking and vaping on cancer-related symptom burden (fatigue, pain, emotional problems) and quality of life.
Breaking New Ground in Breast Cancer Therapy Without Chemotherapy
Scientists are making strides in personalized breast cancer therapy by developing a highly accurate molecular classifier test for breast cancer patients.
 Prostate Cancer 'Test by Request' Policies: Beneficial or Detrimental
Experts suggest high-income countries implement a comprehensive risk-based approach for prostate-specific antigen (PSA) testing to reduce overdiagnosis and overtreatment.
 Oral Cancer Cells Use Fat as Fuel to Escape from Immunity
New study identifies the role of metabolic comorbidities such as obesity in contributing to the immunogenicity of oral cancer through the immune pathway STING-IFN-I.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Therapy Improves Outcomes for Patients With B-cell Lymphoma Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests